Page 45 - Eric Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sold off from Grainger this past September, the company is now China-owned and gaining momentum. May 13th, 2021 MyMRO Shanghai-based MyMRO — formerly Grainger China until Grainger sold off the unit in September 2020 — announced Wednesday that it has completed a new round of financing. The company said it has raised several hundred million yuan, or at least $30 million USD, in a B-round of financing led by China investment firm FountainVest Partners. Grainger first announced the Grainger China divestment in June of 2020 in a move aimed at focusing more on key businesses and geographies. ...

Sunrider Protects from the Sun with the Launch of Oi-Lin® Protective Moisturizer Broad Spectrum SPF 30 Torrance, CA, May 01, 2021 --(PR.com)-- Sunrider International, a global health and wellness direct sales company headquartered in Torrance, California, has recently released Oi-Lin® Protective Moisturizer Broad Spectrum SPF 30, an enhanced reformulation of its best-selling Oi Lin® Deep Moisture Lotion SPF 25. This new ultra-sheer formula has a lighter feel, better absorbency, and even more moisturizing benefits. Oi-Lin® Protective Moisturizer provides broad-spectrum, mineral-based p...

Exscientia CEO Professor Andrew Hopkins Dundee life sciences firm Exscientia has access to almost £400 million after its latest fundraising round. The Dundee University spin-out company uses artificial intelligence (AI) to design drugs. Its latest funding round raised $225m (£162m) with an additional $300m (£216m) available from SoftBank at Exscientia’s discretion. What will the money be used for? Chief executive Andrew Hopkins said the investment would be used to expand the firm’s drug pipeline and discovery capabilities. He said: “All of our investors share Exscientia’s vision to...

Exscientia Announces Investment of up to $525M Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientia's discretion Financing led by SoftBank Vision Fund 2 Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2 i led the Series D and was joined by previous round lead investors, Novo Holdings and funds mana...

Softbank leads $525m round in British drug developer Exscientia Exscientia chief executive Andrew Hopkins (Photo: Exscientia) British pharmaceutical company Exscientia has received funding from Softbank Vision Fund just a month after closing its last investment round.  Exscientia uses artificial intelligence to discover new drug molecules and has now designed two drugs that are in Phase 1 of clinical trials.  The Oxford-based company today announced it had completed a $225m Series D round led by the fund, with an additional $300m equity commitment to be drawn down at the ph...